Tempus AI

TEM

Market cap $9.52B

Since going public in mid-2024, shares of healthcare and life science services company Tempus AI NASDAQ: TEM have gone on a wild rollercoaster ride. The firm's initial public offering price was $37.

In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulatory challenges without losing sight of broader industry shifts.

Tempus AI maintains strong Q4 momentum, with robust testing stats and improving financials despite recent post-earnings stock weakness. Oncology testing volume grew 29% YoY, and net revenue retention reached 126%, signaling strong customer value and recurring demand. Adjusted EBITDA turned positive in Q4, and 2026 guidance projects $65M adjusted EBITDA, though revenue growth is expected to slow to 25%.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST. The live webcast may be accessed directly using the following link: https://event.webcasts.com/starthere.jsp?ei=1753938&tp_k.

Tempus AI NASDAQ: TEM appears to be a smart buy for tech traders as it is a leading provider of AI-enabled services and infrastructure for healthcare, and its stock is set up to rebound robustly. Trading near 52-week lows in late February, the stock is more than 45% below the analysts' consensus, with tailwinds to drive it there.

Tempus AI, Inc. has declined 50% from highs, now trading near support despite robust above $50, despite good Q4 results and strong organic growth. The AI precision medicine company delivered 33% organic growth with Diagnostics revenue expanding due to higher test ASPs. Concerns over AI replacement have pressured the stock, yet TEM's proprietary data and hospital network provide defensible moats.

Yesterday investors watched to see whether Tempus AI's full-year and Q4 2025 results would validate the profitability story that the January pre-announcement left unfinished.

Tempus AI posts Q4 revenue beat with 83% surge, but wider-than-expected loss and operating shortfall send shares down in after-hours trading.

Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript

Tempus AI (TEM) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.18 per share a year ago.